- Home
- Publications
- Publication Search
- Publication Details
Title
Non-nuclear AR Signaling in Prostate Cancer
Authors
Keywords
-
Journal
Frontiers in Chemistry
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-09-26
DOI
10.3389/fchem.2019.00651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Darolutamide for non-metastatic, castration-resistant prostate cancer
- (2019) Talha Burki LANCET ONCOLOGY
- Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
- (2019) Celestia Higano Nature Reviews Urology
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles
- (2017) Jolene Read et al. EUROPEAN JOURNAL OF CANCER
- Membrane androgen receptor characteristics of human ZIP9 (SLC39A) zinc transporter in prostate cancer cells: Androgen-specific activation and involvement of an inhibitory G protein in zinc and MAP kinase signaling
- (2017) Peter Thomas et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy†
- (2017) Nancy L Goicochea et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Stromal Androgen Receptor in Prostate Cancer Development and Progression
- (2017) Damien Leach et al. Cancers
- Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting
- (2016) Raj Kumar ASIAN JOURNAL OF ANDROLOGY
- Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
- (2016) Carmen A. Banuelos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer
- (2016) Rajendra Karki et al. NATURE
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
- (2016) Aerken Maolake et al. Oncotarget
- Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma
- (2015) Kyuichi Kadota et al. Journal of Thoracic Oncology
- Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase
- (2015) Jelani C. Zarif et al. Oncotarget
- Stromal Androgen Receptor in Prostate Development and Cancer
- (2014) Mandeep Singh et al. AMERICAN JOURNAL OF PATHOLOGY
- Androgen biosynthesis in castration-resistant prostate cancer
- (2014) Trevor M Penning ENDOCRINE-RELATED CANCER
- A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides
- (2014) Andrea Guerrini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
- (2014) Carmen A. Banuelos et al. PLoS One
- Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells
- (2014) G Castoria et al. Cell Death & Disease
- Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target
- (2013) E. A. Grimm et al. CLINICAL CANCER RESEARCH
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
- (2013) Kouji Izumi et al. EMBO Molecular Medicine
- Targeting membrane androgen receptors in tumors
- (2013) Florian Lang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
- (2013) T-H Lin et al. Cell Death & Disease
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase
- (2012) Jing Yu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- The immune score as a new possible approach for the classification of cancer
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- The hinge region in androgen receptor control
- (2012) Liesbeth Clinckemalie et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic
- (2012) Niels Halama et al. OncoImmunology
- The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
- (2012) Paul G Corn Cancer Management and Research
- Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity
- (2011) Labros G. Meimetis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
- (2011) Iain J. McEwan Molecular BioSystems
- Androgen-Induced Cell Migration: Role of Androgen Receptor/Filamin A Association
- (2011) Gabriella Castoria et al. PLoS One
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Src signaling in cancer invasion
- (2010) Marcello Guarino JOURNAL OF CELLULAR PHYSIOLOGY
- The role of calcium signaling in phagocytosis
- (2010) Paula Nunes et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Therapeutic targeting of the prostate cancer microenvironment
- (2010) Maria Karlou et al. Nature Reviews Urology
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Tumours with PI3K activation are resistant to dietary restriction
- (2009) Nada Y. Kalaany et al. NATURE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Tumor–stroma co-evolution in prostate cancer progression and metastasis
- (2009) Sajni Josson et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain
- (2008) Philippa Davies et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Sintokamides A to E, Chlorinated Peptides from the SpongeDysideasp. that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells
- (2008) Marianne D. Sadar et al. ORGANIC LETTERS
- Targeting the stromal androgen receptor in primary prostate tumors at earlier stages
- (2008) Y. Niu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Non-genomic actions of androgens
- (2007) C.D. Foradori et al. FRONTIERS IN NEUROENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started